WO2015146896A1 - 多重免疫染色法に基づく生体物質の定量方法 - Google Patents
多重免疫染色法に基づく生体物質の定量方法 Download PDFInfo
- Publication number
- WO2015146896A1 WO2015146896A1 PCT/JP2015/058703 JP2015058703W WO2015146896A1 WO 2015146896 A1 WO2015146896 A1 WO 2015146896A1 JP 2015058703 W JP2015058703 W JP 2015058703W WO 2015146896 A1 WO2015146896 A1 WO 2015146896A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biological material
- fluorescent
- immunostaining
- target biological
- target
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 155
- 238000000034 method Methods 0.000 title claims abstract description 119
- 238000012744 immunostaining Methods 0.000 title claims abstract description 117
- 239000000427 antigen Substances 0.000 title description 13
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 118
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 70
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims description 117
- 239000002105 nanoparticle Substances 0.000 claims description 56
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 33
- 230000001575 pathological effect Effects 0.000 claims description 33
- 238000011002 quantification Methods 0.000 claims description 30
- 238000010186 staining Methods 0.000 claims description 27
- 238000005259 measurement Methods 0.000 claims description 25
- 108050007957 Cadherin Proteins 0.000 claims description 12
- 102000000905 Cadherin Human genes 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 230000000877 morphologic effect Effects 0.000 claims description 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 7
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 7
- 108091006112 ATPases Proteins 0.000 claims description 6
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 6
- 108010076876 Keratins Proteins 0.000 claims description 6
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 230000007170 pathology Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 65
- 239000000523 sample Substances 0.000 description 64
- 239000000243 solution Substances 0.000 description 61
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 60
- 238000002360 preparation method Methods 0.000 description 47
- 230000008569 process Effects 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000003153 chemical reaction reagent Substances 0.000 description 33
- 230000005284 excitation Effects 0.000 description 33
- 229920005989 resin Polymers 0.000 description 32
- 239000011347 resin Substances 0.000 description 32
- 238000001215 fluorescent labelling Methods 0.000 description 30
- 238000012854 evaluation process Methods 0.000 description 25
- 239000000975 dye Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 206010006187 Breast cancer Diseases 0.000 description 20
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 238000012937 correction Methods 0.000 description 19
- 230000000007 visual effect Effects 0.000 description 18
- 238000010517 secondary reaction Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 235000019557 luminance Nutrition 0.000 description 15
- 229920000877 Melamine resin Polymers 0.000 description 14
- 229960002685 biotin Drugs 0.000 description 14
- 239000011616 biotin Substances 0.000 description 14
- 238000010827 pathological analysis Methods 0.000 description 14
- 108090001008 Avidin Proteins 0.000 description 13
- 239000004640 Melamine resin Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 239000004065 semiconductor Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 108010090804 Streptavidin Proteins 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical class [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 108091008147 housekeeping proteins Proteins 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 239000012114 Alexa Fluor 647 Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 229940022353 herceptin Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 208000005156 Dehydration Diseases 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- -1 CdSe Chemical class 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003573 thiols Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008393 encapsulating agent Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UDPCXVIKHFVPSZ-HOIFWPIMSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O UDPCXVIKHFVPSZ-HOIFWPIMSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 229910005793 GeO 2 Inorganic materials 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910000673 Indium arsenide Inorganic materials 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 229910007709 ZnTe Inorganic materials 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007849 furan resin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229910021480 group 4 element Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 1
- 238000012690 ionic polymerization Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/80—Multi-analyte reference solutions containing cholesterol, glucose and the like
Definitions
- the present invention relates to a method for quantifying a biological substance (target biological substance) expressed in a cell membrane of a tissue section. Specifically, the present invention relates to a method for quantifying target cells using a multiple immunostaining method in which each of a target biological material and a biological material other than the target biological material (reference biological material) is immunostained using a fluorescent label. About.
- Pathological diagnosis is the observation of materials collected from the human body (specimens prepared from specimens of cells, tissues, etc.) with a microscope, and the use of pathological knowledge and techniques to diagnose the presence and type of lesions. Has been done in the medical field to determine treatment and surgery policies.
- HER2 human epidermal growth factor receptor
- Herceptin registered trademark, general name: trastuzumab
- DAB staining is a dye staining method that uses peroxidase as a labeling enzyme and diaminobenzidine (DAB) as a substrate, and the enzyme reaction results in a brown color that allows observation of the site where the antigen is present in a bright field (light microscope). Can develop color.
- DAB staining is a dye staining method that uses peroxidase as a labeling enzyme and diaminobenzidine (DAB) as a substrate, and the enzyme reaction results in a brown color that allows observation of the site where the antigen is present in a bright field (light microscope). Can develop color.
- the dye staining method using an enzyme label such as DAB staining has a problem that it is difficult to estimate the actual antibody expression level from the staining concentration because the staining concentration greatly depends on environmental conditions such as temperature and time. There is.
- a method that uses a fluorescent label instead of an enzyme label and can express an antigen with a fluorescent bright spot that can be observed with a dark field (fluorescence microscope, confocal laser microscope) It has come to be used in immunohistochemical staining.
- a biological substance existing in a cell membrane is labeled with inorganic semiconductor nanoparticles, or particles containing fluorescent organic dyes or inorganic semiconductor nanoparticles (fluorescent substance-containing nanoparticles), while the cell membrane itself is also nonspecific. Stained with a fluorescent substance that binds to the target, such as eosin or a PKH dye (trade name “CellVue” (registered trademark), having a strong fluorescent coloring site and a long tail with lipid affinity bound to it).
- a fluorescent substance that binds to the target such as eosin or a PKH dye (trade name “CellVue” (registered trademark), having a strong fluorescent coloring site and a long tail with lipid affinity bound to it).
- Patent Document 2 a target protein to be quantified in a sample and a control protein are stained with antibodies labeled with different fluorescent dyes, and the total fluorescence intensity of each of the stained target protein and control protein is calculated.
- a method has been proposed in which the ratio between the total fluorescence intensity of the target protein and the total fluorescence intensity of the control protein is used as a quantitative value of the target protein.
- the target protein in the method described in Patent Document 2 include proteins that serve as anticancer drug sensitivity markers, proteins that are associated with side effects of anticancer drugs, proteins that serve as markers for prognostic factors, diagnostic key proteins (mainly secreted proteins), and the like.
- Various proteins specifically expressed in cancer cells are mentioned.
- examples of the reference protein include proteins (housekeeping proteins) encoded by housekeeping genes constitutively expressed in the cytoplasm, such as ⁇ -actin and GAPDH (glyceraldehyde-3-phosphate dehydrogenase). ing.
- Sections (pathological specimens) of cells, tissues, organs, etc. used for pathological diagnosis change the preservation state and the degree of protein denaturation in the specimen depending on factors such as time to fixation and fixation time during the preparation process. .
- the antibody recognition rate in the antigen-antibody reaction varies.
- Even if the expression level of the target protein is the same, the amount of protein detected on a planar stained image varies depending on the thickness of the slice when the fixed specimen is sliced (the thicker the slice, the greater the detected amount). Therefore, even when observed using a plurality of specimens cut from tissues that should have substantially the same expression level of the target protein, the quantitative values based on fluorescent substances such as fluorescent substance-containing nanoparticles differ. There was a problem.
- the target protein specifically bound to the cell membrane is bound. While extracting the signal derived from the phosphor, it is necessary to exclude as much as possible the signal derived from the phosphor adsorbed nonspecifically to a substance other than the target protein in the cytoplasm.
- the pathology includes a non-specifically adsorbed phosphor as described above. Signals derived from all phosphors present in the specimen are used for quantification, and only the target protein present on the cell membrane cannot be accurately quantified.
- the cell size varies from sample to sample, and the relative size of the cell membrane region on the stained image (compared to the cytoplasmic region) is smaller when the cell is larger than when the cell is small. . Therefore, as described in Patent Document 2, the ratio of the total fluorescence intensity derived from the target protein mainly present on the cell membrane to the total fluorescence intensity derived from the housekeeping protein present in the cytoplasm as the reference protein.
- the evaluation value is lower when the cell is large than when the cell is small.
- the housekeeping protein used as the reference protein in the invention described in Patent Document 2 is mainly present in the cytoplasm, while the target protein is mainly present on the cell membrane. Since the degradation state at the time of specimen preparation differs between the cytoplasm part and the cell membrane part, the total fluorescence derived from the target protein existing on the cell membrane relative to the total fluorescence intensity derived from the housekeeping protein present in the cytoplasm as the reference protein The value of the intensity ratio is affected by such a difference in the deterioration state, and the expression level of the target protein on the cell membrane cannot be correctly evaluated regardless of the deterioration state of the cell membrane portion.
- Patent Document 2 specifically discloses only an embodiment in which only one type of housekeeping protein is used as a reference protein, but a sample in which the expression level of the housekeeping protein is significantly different from a normal sample. There is a possibility that a homogeneous evaluation in the judgment of the indication of a molecular target drug or the like cannot be given to samples collected from a wide range of patients, which may contain a mixture of drugs.
- Patent Document 1 a substance that non-specifically binds to the cell membrane is used as a substance for staining the cell membrane. This is not the same as the effect on staining of biological material (target protein) existing on the cell membrane based on specific binding by antibody reaction. Further, Patent Document 1 describes that only the fluorescence labeled with a biological material existing on the cell membrane is extracted using fluorescence obtained by staining the cell membrane, and the biological material is quantified. The technical idea of correcting the fluorescence signal (luminance or the number of bright spots) labeled with the biological substance existing on the cell membrane using the fluorescence signal (luminance) stained with No. 1 is not described.
- the present invention provides a quantification method capable of more accurately quantifying a biological substance expressed in a cell membrane in a pathological specimen, excluding the influence of the deterioration state at the time of specimen preparation on the fluorescence intensity. Is an issue.
- the present inventors immunostained a biological material (preferably two or more types of such biological materials) different from the target biological material constantly expressed in the cell membrane together with the target biological material using a phosphor.
- a biological material preferably two or more types of such biological materials
- the present inventors have found that the influence of the variation in the quality of the obtained sample can be corrected so as to be excluded from the fluorescent labeling signal of the target biological material, and the present invention has been completed.
- the present invention includes the following inventions.
- [Claim 1] A method for quantifying a biological substance (target biological substance) expressed on a cell membrane in a pathological specimen, (1a) a step of immunostaining the target biological substance using a phosphor; (1b) a step of immunostaining a biological material (reference biological material) different from the target biological material constantly expressed in the cell membrane using a fluorescent material different from the fluorescent material for the target biological material; (2) Using the immunostained image of the target biological material and the immunostained image of the reference biological material, the position of the fluorescent label signal corresponding to the target biological material in the region of the cell membrane is specified, and the cell membrane A step of measuring a fluorescent label signal corresponding to the target biological material in the region and a fluorescent label signal corresponding to the reference biological material, and (3) in the region of the cell membrane for the entire measurement target region or for each cell A step of correcting the measured value of the fluorescent label signal corresponding to the target biological material in the sample using the measured value of the fluorescent label signal corresponding to the reference biological material and using it as an index
- Step (3) by dividing the measured value of the fluorescent label signal corresponding to the target biological substance in the region of the cell membrane by the measured value of the fluorescent label signal corresponding to the reference biological substance, the measured value of the signal is obtained.
- Item 2 The quantification method according to Item 1, comprising a step of correcting the expression level as an index for quantifying the expression level.
- Item 9 The quantification method according to any one of Items 1 to 8, wherein the reference biological material is one type or two or more types selected from the group consisting of ATPase, cadherin, cytokeratin, and EpCAM.
- a kit for carrying out the target biological substance quantification method according to any one of Items 1 to 9, A kit comprising an antibody and a phosphor for producing the immunostaining agent for the target biological material, and an antibody and a phosphor for producing the immunostaining agent for the reference biological material.
- the accuracy of extraction and quantification of the target biological substance expressed in the cell membrane can be improved, and the accuracy of the determination for pathological diagnosis, particularly for estimating the effect of the molecular target drug, can be improved. Can be improved.
- FIG. 1A is a flowchart showing an embodiment of a biological material quantification method based on the multiple immunostaining method according to the present invention.
- FIG. 1A is a diagram showing an example of the entire process
- FIG. 1B is a diagram showing only the steps related to claim 1.
- FIG. 1B is a diagram showing an excerpt of the basic steps constituting the present invention.
- FIG. 2 is a first immunostained image taken in Example 9 and fluorescently labeled with the target biological material (HER2) with Texas Red-encapsulated melamine resin nanoparticles (shown in red in the color photograph). What is indicated by an arrow is a portion where the target biological material is stained.
- FIG. 1A is a flowchart showing an embodiment of a biological material quantification method based on the multiple immunostaining method according to the present invention.
- FIG. 1A is a diagram showing an example of the entire process
- FIG. 1B is a diagram showing only the steps related to claim 1.
- FIG. 1B is a diagram
- FIG. 3 is a second immunostained image obtained by fluorescently labeling reference biological materials (ATPase, cadherin, cytokeratin, and EpCAM) with Alexa Fluor 647 dye molecule, which was photographed in Example 9 (shown in green in the color photograph). is there). What is indicated by an arrow is a portion where the reference biological material is stained and indicates a cell membrane region.
- FIG. 4 is an immunostained image obtained by superimposing the first immunostained image of FIG. 2 and the second immunostained image of FIG. What is indicated by an arrow is a portion where the stained portions of the first immunostained image and the second immunostained image overlap, that is, HER2 on the cell membrane region.
- the target biological material which is the first biological material in the present invention, is a biological material expressed in the cell membrane of a tissue section, particularly a protein (antigen), and is mainly used for quantification or detection from the viewpoint of pathological diagnosis. , Refers to a target for immunostaining using a fluorescent label.
- the reference biological material which is the second biological material in the present invention, is a biological material, particularly a protein (antigen), that is different from the target biological material that is constantly expressed in the cell membrane of the tissue section.
- a biological material particularly a protein (antigen)
- it refers to a target for immunostaining using a fluorescent label.
- the target biological material may be selected in consideration of the use of the quantification method of the present invention such as pathological diagnosis, and is not particularly limited.
- a biological substance that is expressed in the cell membrane of various cancer tissues and can be used as a biomarker such as EGFR (HER1) (Epidermal Growth Factor Receptor: epidermal growth factor receptor)
- HER2 Human epidermal growth factor receptor
- HER3, HER4, VEGFR Vasular Endothelial Growth Factor Receptor: vascular endothelial growth factor receptor
- IGFR Insulin-like Growth Factor ⁇ ⁇ Receptor
- HGFR Hepatocyte Growth Factor Receptor growth factor receptors (receptors)
- PD-1 Programmed cell ⁇ death 1
- other proteins that are immune system receptors Can be mentioned.
- EGFR / HER includes EGFR / HER1 (also referred to as ErbB1) that is overexpressed in cancer tissues such as colorectal cancer, EGFR2 / HER2 (also referred to as ErbB2, neu) that is overexpressed in cancer tissues such as breast cancer, and EGFR3. / HER3 and EGFR4 / HER4 are included.
- VEGFR includes VEGFR-1 (also referred to as Flt-1), VEGFR-2 (also referred to as Flt-2, KDR) and lymphatic vessels, which are upregulated in vascular endothelial cells in cancer tissues such as liver cancer and esophageal cancer.
- VEGFR-3 also called Flt-4) whose expression is upregulated in the skin cells is included.
- HER2 is suitable as a target biological material when performing the quantification method of the present invention in pathological diagnosis related to breast cancer.
- the reference biological material is selected from biological materials whose expression level does not vary greatly even in a specific disease, unlike the target biological material.
- membrane proteins such as ATPase, cadherin, cytokeratin, EpCAM (Epithelial Cell Adhesion / Activating Molecule: also called epithelial cell adhesion molecule, CD326, KSA or TROP1) can be a preferred reference biological material in the present invention.
- the reference biological material may be one type, but preferably two or more types.
- fluctuations in the sum of the expression levels can be further suppressed, and a cell membrane image (cell membrane region) can be formed with a large number of fluorescent labels. Stability as a biological material can be improved.
- the first immunostaining agent in the present invention is a substance for fluorescently labeling a target biological substance by immunostaining, and includes at least a probe that specifically binds to the target biological substance and a phosphor.
- the second immunostaining agent in the present invention is a substance for fluorescently labeling a reference biological substance by immunostaining, and includes at least a probe that specifically binds to the reference biological substance and a phosphor.
- an antibody that specifically recognizes and binds to the protein as the target biological material as an antigen as described above can be used.
- an anti-EGFR antibody can be used as the first probe
- HER2 is the target biological material
- the anti-HER2 antibody can be used as the first probe.
- an antibody that specifically recognizes and binds to the protein as the reference biological substance as an antigen as described above can be used.
- an anti-cadherin antibody can be used as the second probe.
- Both the antibodies as the first and second probes may be polyclonal antibodies, but monoclonal antibodies are preferred from the viewpoint of quantitative stability.
- the type of animal that produces the antibody is not particularly limited, and may be selected from mice, rats, guinea pigs, rabbits, goats, sheep, and the like as in the past.
- the antibody as a probe may be an antibody fragment or a derivative instead of a natural full-length antibody as long as it has the ability to specifically recognize and bind to a specific biological substance (antigen). That is, the term “antibody” in the present specification includes not only full-length antibodies but also antibody fragments such as Fab, F (ab) ′ 2 , Fv, scFv and chimeric antibodies (humanized antibodies, etc.), multifunctional antibodies Derivatives such as are included.
- the phosphor for the first immunostaining agent (first phosphor) and the phosphor for the second immunostaining agent (second phosphor) are selected from various known phosphors used in the technical field. It can be selected and is not particularly limited. Representative phosphors include inorganic semiconductor nanoparticles (also referred to as “quantum dots”), organic fluorescent dyes, and their aggregates.
- the “phosphor” in this specification is irradiated with electromagnetic waves (X-rays, ultraviolet rays, or visible rays) having a predetermined wavelength and absorbs energy to excite electrons and return from the excited state to the ground state.
- electromagnetic waves X-rays, ultraviolet rays, or visible rays
- a substance that emits surplus energy as electromagnetic waves that is, a substance that emits "fluorescence” and that can be combined with a “probe”.
- fluorescence has a broad meaning and includes phosphorescence having a long emission lifetime in which emission is continued even when irradiation of electromagnetic waves for excitation is stopped, and narrow sense fluorescence having a short emission lifetime.
- Inorganic semiconductor nanoparticles include those containing II-VI group compounds, III-V group compounds, or group IV elements, such as CdSe, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN. , InAs, InGaP, GaP, GaAs, Si, Ge, and the like.
- those having these inorganic semiconductor nanoparticles as a core and a shell formed on the outside thereof for example, CdSe / ZnS, CdS / ZnS, InP / ZnS, InGaP / ZnS, Si / SiO 2 , Si / ZnS, Ge Core / shell type inorganic semiconductor nanoparticles such as / GeO 2 and Ge / ZnS can also be used.
- Organic fluorescent dyes examples include rhodamine dye molecules, squarylium dye molecules, cyanine dye molecules, aromatic ring dye molecules, oxazine dye molecules, carbopyronine dye molecules, and pyromesene dye molecules. Can do.
- Alexa Fluor registered trademark, manufactured by Invitrogen
- BODIPY registered trademark, manufactured by Invitrogen
- Cy registered trademark, manufactured by GE Healthcare
- DY dye molecule registered trademark, manufactured by DYOMICS
- HiLyte registered trademark, manufactured by Anaspec
- dye molecule DyLight (registered trademark, manufactured by Thermo Scientific)
- ATTO registered trademark, manufactured by ATTO-TEC
- MFP registered trademark, manufactured by Mobitec
- Fluorescent substance integrated nanoparticle As an aggregate of fluorescent substances, a particle made of an organic or inorganic substance is used as a base, and a plurality of fluorescent substances are included in and / or adsorbed on the surface thereof. “Fluorescent substance integrated nanoparticles” which are nano-sized particles can be mentioned. In this case, it is preferable that the base (for example, resin) and the fluorescent substance (for example, organic fluorescent dye) have substituents or sites having charges opposite to each other, and that electrostatic interaction works. .
- the fluorescent substance to be encapsulated in the fluorescent substance integrated nanoparticles in addition to the inorganic semiconductor nanoparticles and fluorescent dye molecules as described above, for example, Y 2 O 3 , Zn 2 SiO 4 or the like is used as a base material, and Mn 2+ , Eu 3 Examples include “long afterglow phosphors” using + or the like as an activator.
- the organic substance is a resin generally classified as a thermosetting resin such as melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, furan resin; Resins generally classified as thermoplastic resins such as styrene resin, acrylic resin, acrylonitrile resin, AS resin (acrylonitrile-styrene copolymer), ASA resin (acrylonitrile-styrene-methyl acrylate copolymer); polylactic acid Other resins such as: polysaccharides can be exemplified, and silica (glass) can be exemplified as the inorganic substance.
- a thermosetting resin such as melamine resin, urea resin, aniline resin, guanamine resin, phenol resin, xylene resin, furan resin
- Resins generally classified as thermoplastic resins such as styrene resin, acrylic resin, acrylonitrile resin, AS resin (acrylonitrile-styrene cop
- Fluorescent substance-integrated nanoparticles can be produced according to a known method (for example, see JP2013-57937A). More specifically, for example, the fluorescent substance-encapsulating silica particles having silica as a base material and encapsulating the fluorescent substance therein are inorganic substances such as inorganic semiconductor nanoparticles, organic fluorescent dyes, and tetraethoxysilane. It can be produced by dropping a solution in which the silica precursor is dissolved into a solution in which ethanol and ammonia are dissolved and hydrolyzing the silica precursor.
- a resin solution or a dispersion of fine particles is prepared in advance.
- it can be prepared by adding a fluorescent substance such as inorganic semiconductor nanoparticles or organic fluorescent dye and stirring the mixture.
- fluorescent substance-containing resin particles can also be produced by adding a fluorescent dye to the resin raw material solution and then allowing the polymerization reaction to proceed.
- a thermosetting resin such as a melamine resin
- a raw material of the resin monomer or oligomer or prepolymer, for example, methylol melamine which is a condensate of melamine and formaldehyde
- an organic fluorescent dye
- the organic fluorescent dye-containing resin particles can be prepared by heating a reaction mixture further containing a surfactant and a polymerization reaction accelerator (such as an acid) and advancing the polymerization reaction by an emulsion polymerization method.
- thermoplastic resin such as a styrene copolymer
- an organic fluorescent dye is bonded in advance as a resin raw material monomer by a covalent bond or the like.
- the reaction mixture containing a polymerization initiator (benzoyl peroxide, azobisisobutyronitrile, etc.) is heated and the polymerization reaction proceeds by radical polymerization or ionic polymerization.
- a polymerization initiator benzoyl peroxide, azobisisobutyronitrile, etc.
- the average particle diameter of the fluorescent substance-integrated nanoparticles is not particularly limited as long as it is a particle diameter suitable for immunostaining of a pathological specimen. Considering the ease of detection, etc., it is usually 10 to 500 nm, preferably 50 to 200 nm.
- the coefficient of variation indicating the variation in particle size is usually 20% or less, preferably 5 to 15%.
- the fluorescent substance integrated nanoparticles satisfying such conditions can be manufactured by adjusting the manufacturing conditions. For example, when producing fluorescent substance-integrated nanoparticles by emulsion polymerization, the particle size can be adjusted by the amount of surfactant to be added. If the amount of the active agent is relatively large, the particle size tends to be small, and if the amount is relatively small, the particle size tends to be large.
- the particle diameter of the fluorescent substance-integrated nanoparticles is obtained by taking an electron micrograph using a scanning electron microscope (SEM), measuring the cross-sectional area of the fluorescent substance-integrated nanoparticles, and assuming that the cross-sectional shape is a circle. Further, it can be calculated as the diameter of a circle corresponding to the cross-sectional area.
- the average particle size and coefficient of variation of a group consisting of a plurality of fluorescent material-integrated nanoparticles are calculated as described above for a sufficient number (for example, 1000) of fluorescent material-integrated nanoparticles, and the average particle size is The coefficient of variation is calculated by the formula: 100 ⁇ standard deviation of particle diameter / average particle diameter.
- the “fluorescent dye-containing nanoparticle” is preferred as the first phosphor, and the “fluorescent dye” is preferred as the second phosphor.
- the fluorescent dye-encapsulated nanoparticles for fluorescently labeling the target biological substance can emit fluorescence having a sufficient intensity to express the target biological substance as a bright spot for each molecule, and the fluorescent dye for fluorescently labeling the reference biological substance is This is because the signal of the target biological substance (the bright spot) can be appropriately corrected, and fluorescence having an intensity reflecting the deterioration state at the time of specimen preparation can be emitted.
- the present invention is not limited to the embodiment using these first phosphor and second phosphor.
- the embodiment uses inorganic semiconductor nanoparticles as the first phosphor and fluorescent dye as the second phosphor.
- the form may be sufficient and embodiment using the fluorescent dye inclusion
- inner_cover nanoparticle which emits fluorescence of a mutually different wavelength as a 1st fluorescent substance and a 2nd fluorescent substance may be sufficient.
- the first and second immunostaining agents are not particularly limited as long as the target biological material and the reference biological material can be fluorescently labeled and a signal capable of obtaining useful data for pathological diagnosis can be obtained.
- various known immunostaining agents can be used.
- an immunostaining agent a probe and a fluorophore that are directly linked, that is, via a linker molecule, if necessary, may be used.
- the probe and the phosphor are linked indirectly, that is, by a bond other than a covalent bond using an antigen-antibody reaction or an avidin / biotin reaction. It is preferable to use a complex.
- the fluorescent substance contained in the first immunostaining agent for fluorescently labeling the target biological substance is preferably “fluorescent dye-encapsulated nanoparticles” as described above.
- a first immunostaining agent in which a probe and a phosphor are indirectly linked [antibody against a target biological substance (primary antibody as a probe)]... [Antibody against a primary antibody (secondary antibody)]-[ Biotin] / [Avidin]-[Fluorescent substance (fluorescent dye-encapsulated nanoparticle)] (where "" indicates binding by antigen-antibody reaction, and "-" passes through a linker molecule as necessary.
- a complex consisting of three molecules that are linked in a manner such as “/” indicates that they are bound by an avidin-biotin reaction. .
- the “fluorescent dye” is preferable as the phosphor contained in the second immunostaining agent for fluorescently labeling the reference biological substance.
- a second immunostaining agent in which a probe and a phosphor are indirectly linked [an antibody against a reference biological material (primary antibody as a probe)]... [An antibody against a primary antibody (secondary antibody)]-[ Fluorescent substance (fluorescent dye)] (where "! indicates binding by an antigen-antibody reaction, and "-" is bonded by a covalent bond which may be via a linker molecule if necessary. And a complex composed of two molecules connected by a mode.
- the secondary antibody to be bound to the primary antibody to the target biological material is different from the secondary antibody to be bound to the primary antibody to the reference biological material in order to avoid unintentional binding.
- the type of antibody for example, mouse IgG is used as a primary antibody against a target biological material, and an anti-mouse IgG antibody is used as a secondary antibody against the IgG, while rabbit IgG is used as a primary antibody against a reference biological material, and anti-rabbit IgG is used as a secondary antibody thereto.
- An antibody may be used.
- the primary antibody and the secondary antibody can be prepared according to a conventional method, or commercially available antibodies can be used.
- the secondary antibody-biotin conjugate uses, for example, a commercially available biotin labeling reagent (kit) based on a known technique that can bind biotin to a desired antibody (protein). Can be produced.
- a biotin-modified secondary antibody itself in which biotin is bound to a desired antibody is commercially available, it may be used.
- a phosphor-avidin conjugate (avidin-modified phosphor) can also be prepared using a commercially available avidin labeling reagent (kit), for example, based on a known technique capable of binding avidin to the phosphor. it can.
- the avidin in this case may be an improved type such as streptavidin or neutravidin that has a higher binding force with biotin than avidin.
- the method for producing the phosphor-avidin conjugate are as follows.
- the fluorescent substance is a fluorescent substance-integrated nanoparticle based on a resin
- functional groups such as amino groups can be used for melamine resins, and monomers such as acrylic resins and styrene resins can be copolymerized with monomers having functional groups (for example, epoxy groups) in the side chains.
- the functional group itself or a functional group converted from the functional group can be used, and further, the functional group can be used for another functional group.
- Groups can also be introduced.
- the phosphor is a fluorescent substance integrated nanoparticle or inorganic semiconductor nanoparticle based on silica
- a desired functional group can be introduced by surface modification with a silane coupling agent, for example, aminopropyltrimethoxy. If silane is used, an amino group can be introduced.
- a thiol group can be introduced by reacting N-succinimidyl S-acetylthioacetate (SATA) with the amino group of avidin.
- SATA N-succinimidyl S-acetylthioacetate
- a phosphor having a group can be linked to avidin into which a thiol group is introduced.
- the secondary antibody-fluorescent dye conjugate (fluorescent labeled secondary antibody) can be obtained, for example, by a commercially available fluorescent labeling reagent (fluorescent labeled reagent (protein)) based on a known technique capable of binding a desired fluorescent dye to a desired antibody (protein). Kit). Further, if a fluorescently labeled secondary antibody itself in which a desired fluorescent dye is bound to a desired antibody in advance is commercially available, it may be used.
- the target biological material quantification method includes at least the following steps: (1a) a step of immunostaining the target biological substance using a phosphor (first immunostaining step); (1b) a step of immunostaining the reference biological material using a phosphor different from the phosphor for the target biological material (second immunostaining step); (2) For the immunostained image of the target biological material and the immunostained image of the reference biological material, a fluorescent label signal corresponding to the target biological material and a fluorescent label signal corresponding to the reference biological material are measured, and a region of the cell membrane
- a step (image processing / measurement step) of extracting a fluorescent labeling signal corresponding to the target biological substance in the cell and image processing / measurement process): A step of correcting the measured value of the fluorescent labeling signal corresponding to (2) using the measured value of the fluorescent labeling signal corresponding to the reference biological material and using it as an index for quantifying the expression level (correction step).
- first immunostaining step and the second immunostaining step may be performed after one of the steps is performed first, or may be performed simultaneously.
- the target biological substance quantification method according to the present invention usually includes a sample pretreatment step, a sample posttreatment step and the like in addition to the above steps. Specifically, these steps are performed by the following procedure, for example.
- Pathological specimens are often stored in a state where sections of cells, tissues, organs and the like are embedded in paraffin. In order to immunostain such a section, the section is usually subjected to deparaffinization and antigen activation prior to immunostaining.
- the deparaffinization process is performed, for example, by immersing the pathological section in xylene to remove paraffin, then immersing the pathological section in ethanol to remove xylene, and then immersing the pathological section in water to remove ethanol. Just do it. These three operations are usually performed at room temperature. Further, each immersion time may be about 3 to 30 minutes, and each treatment solution may be exchanged during the immersion if necessary.
- the antigen activation treatment is performed, for example, by immersing the pathological specimen after the deparaffinization treatment in an activation solution (0.01 M citrate buffer solution, 1 mM EDTA aqueous solution, 5% urea aqueous solution, 0.1 M Tris-HCl buffer solution, etc.). And then heating, followed by washing by immersing the pathological specimen in PBS.
- an activation solution 0.01 M citrate buffer solution, 1 mM EDTA aqueous solution, 5% urea aqueous solution, 0.1 M Tris-HCl buffer solution, etc.
- the temperature may be 50 to 130 ° C. and the time may be 5 to 30 minutes.
- the immersion in PBS is usually about 3 to 30 minutes at room temperature, and if necessary, the PBS may be exchanged during the immersion.
- the first immunostaining step for immunostaining the target biological material is a step of immunostaining a pathological specimen using the first immunostaining agent as described above. It is.
- the first immunostaining agent is one in which the probe and the phosphor are directly connected
- the pathological specimen after the activation process may be immersed in a solvent containing the first immunostaining agent.
- the first immunostaining agent is a complex in which the probe and the phosphor are indirectly linked, a pathological specimen is sequentially immersed in a plurality of reagents for forming the complex. do it.
- the first immunostaining agent is a complex of [primary antibody (probe)] ... [secondary antibody]-[biotin] / [avidin]-[fluorescent dye-containing nanoparticle (phosphor)]
- a treatment in which a pathological specimen is immersed in a primary antibody (probe) solution (sometimes referred to herein as “reagent I”), and then a secondary antibody-biotin conjugate solution (Sometimes referred to herein as “reagent II”) a treatment in which a pathological specimen is immersed (secondary reaction treatment), and finally a solution of avidin-fluorescent dye-containing nanoparticles (herein referred to as “reagent III”)
- a treatment fluorescence labeling treatment for immersing the pathological specimen in the substrate may be performed.
- Conditions and conditions for performing the first immunostaining step for example, the temperature and the immersion time when the pathological specimen is immersed in a predetermined solution (reagent) in each of the primary reaction process, the secondary reaction process, and the fluorescent labeling process, According to the immunostaining method, it can be appropriately adjusted so as to obtain an appropriate signal.
- Second immunostaining step immunostaining of reference biological material
- the second immunostaining step for immunostaining the reference biological material is a step of immunostaining a pathological specimen using the second immunostaining agent as described above. It is.
- the second immunostaining agent is such that the probe and the phosphor are directly connected
- the pathological specimen after the activation step may be immersed in a solvent containing the second immunostaining agent.
- the second immunostaining agent is a complex in which the probe and the phosphor are indirectly linked
- the pathological specimen is sequentially immersed in a plurality of reagents for forming the complex. do it.
- the second immunostaining agent is a complex of [primary antibody (probe)]... [Secondary antibody]-[fluorescent dye (fluorescent substance)], the first antibody (probe) solution
- the pathological specimen is immersed in the reagent (sometimes referred to as “reagent i”) (primary reaction process), and then a secondary antibody-fluorescent dye conjugate solution (herein referred to as “reagent ii”). It is only necessary to perform a process (secondary reaction / fluorescence labeling process) of immersing the pathological specimen in the sample.
- the reagent i includes two or more types of antibodies corresponding to each reference biological material so that all the reference biological materials are immunostained at once. It is.
- Conditions and conditions for performing the second immunostaining step for example, the temperature and the immersion time when the pathological specimen is immersed in a predetermined solution (reagent) in each of the primary reaction process and the secondary reaction / fluorescence labeling process, According to the immunostaining method, it can be appropriately adjusted so as to obtain an appropriate signal.
- a morphological observation staining step for enabling observation of the morphology of cells, tissues, organs, etc. in a bright field can be included.
- the morphological observation staining step can be performed according to a conventional method. For morphological observation of tissue specimens, staining using eosin, in which cytoplasm, stroma, various fibers, erythrocytes, and keratinocytes are stained from red to dark red, is typically used.
- hematoxylin in which cell nuclei, lime, cartilage tissue, bacteria, and mucus are stained blue-blue to light blue
- HE staining eosin staining
- the pathological specimen that has undergone the first and second immunostaining is preferably subjected to treatment such as immobilization / dehydration, penetration, and encapsulation so as to be suitable for observation.
- the immobilization / dehydration treatment may be performed by immersing the pathological specimen in a fixation treatment solution (crosslinking agent such as formalin, paraformaldehyde, glutaraldehyde, acetone, ethanol, methanol).
- a fixation treatment solution crosslinking agent such as formalin, paraformaldehyde, glutaraldehyde, acetone, ethanol, methanol.
- a clearing solution xylene or the like.
- the encapsulating process may be performed by immersing the pathological specimen that has undergone the penetration process in the encapsulating liquid. Conditions for performing these treatments, for example, the temperature and immersion time when the pathological specimen is immersed in a predetermined treatment solution, can be appropriately adjusted according to the conventional immunostaining method so as to obtain an appropriate signal. it can.
- a stained image (first immunostained image) obtained by the first immunostaining step and a stained image (second immunostained image) obtained by the second immunostaining step are obtained.
- the excitation light corresponding to the first phosphor fluorescently labeled with the target biological substance used in the first immunostaining step, and the second immunostaining step are irradiated with excitation light corresponding to the second fluorescent substance that is fluorescently labeled with the used reference biological substance, and each immunostained image by fluorescence emitted from these fluorescent substances is observed and photographed.
- the excitation light in the observation process is not particularly limited as long as the fluorescence emitted by the phosphor for immunostaining agent can be identified in relation to the autofluorescence of the tissue section, but from the viewpoint that the autofluorescence from the tissue section does not become too high.
- Excitation light having a wavelength of 550 to 630 nm is preferred.
- the excitation light can be irradiated by using, for example, a laser light source provided in the fluorescence microscope and an excitation light filter that selectively transmits a predetermined wavelength as required.
- the excitation light of both wavelengths can be irradiated from the same laser light source by switching the excitation light filter.
- Imaging of an immunostained image can be performed, for example, with a digital camera provided in a fluorescence microscope.
- a fluorescent filter that selectively transmits a predetermined wavelength as necessary, so that only the target fluorescence is included, and excitation light that causes unwanted fluorescence or noise and An immunostained image in which other light is excluded can be taken.
- the wavelength of the fluorescence emitted from the first phosphor and the wavelength of the fluorescence emitted from the second phosphor need to be different from each other so that they can be distinguished from each other, immunostaining of each fluorescence while switching the fluorescence filter Just take a picture.
- Image processing / measurement process In the image processing / measurement step, a fluorescent label corresponding to the target biological material is obtained based on the image processing for each of the first immunostained image taken for the target biological material and the second immunostained image taken for the reference biological material. The signal and the fluorescent label signal corresponding to the reference biological material are measured, and the position of the fluorescent label signal corresponding to the target biological material in the region of the cell membrane is specified.
- Fluorescent label signal may be handled as fluorescence intensity (luminance) or as the number of fluorescent bright spots.
- the signal is preferably treated as a bright spot, and when using a fluorescent dye as the reference biological material, the signal is treated as the fluorescence intensity. Is preferred.
- Examples of software that can be used for image processing include “ImageJ” (open source).
- image processing software bright spots with a predetermined wavelength (color) are extracted from the immunostained image and the sum of the brightness is calculated, or the number of bright spots with a predetermined brightness or higher is measured. It is possible to semi-automatically and rapidly perform the processing to be performed, particularly the processing for performing the first embodiment and the second embodiment described below.
- the fluorescence labeling signal is measured, and at the same time, the fluorescence corresponding to the target biological substance existing in the region of the cell membrane of the stained image (that is, on the cell membrane).
- the label signal can be identified and extracted.
- preferred embodiments include the following first and second embodiments, for example. A form is mentioned.
- the first embodiment includes the following steps (2a-1), (2a-2) and (2a-3): (2a-1) Extracting the bright spot of the fluorescent dye from the immunostained image of the reference biological material (see FIG. 3) to form a cell membrane region image, and calculating the sum of the brightness of the bright spots in the cell membrane region as the reference biological material Measuring as a fluorescent label signal of (2a-2)
- the immunostained image of the target biological material is superimposed on the cell membrane region image (see FIG. 4), and the number of bright spots of the fluorescent dye-containing nanoparticles inside the cell membrane region is determined as the fluorescence of the target biological material.
- Measuring as a labeled signal (2a-3) A step of using a measured value corrected by dividing the number of bright spots in the cell membrane region by the sum of the luminances of the fluorescent dyes as an index value for quantifying the expression level of the target biological substance.
- the immunostained image of the reference biological material is used for correcting the fluorescent labeling signal of the target biological material, and the fluorescent labeling of the target biological material contained in the cell membrane region image is formed. It is used to extract only the signal (bright spot). Therefore, separate staining for detecting cell membranes (for example, DAB staining that enables bright-field observation) is unnecessary in the present invention.
- the second embodiment includes the following steps (2b-1), (2b-2) and (2b-3): (2b-1) From the immunostained image of the target biological substance (see FIG. 2), the bright spot of the fluorescent dye-containing nanoparticle is extracted according to the bright spot extraction program to form a cell membrane area image, and the brightness in the cell membrane area Measuring the score as a fluorescent labeling signal of the target biological substance; (2b-2) a step of superimposing an immunostained image of the reference biological material (see FIG.
- the bright spot extraction program in the step (2b-1) a method that can appropriately extract bright spots even when there is unevenness in brightness, for example, a top hat method, can be mentioned.
- a cell membrane region image is formed by using an appropriate bright spot extraction program only from an immunostained image of the target biological material, and the target biological material included therein is included therein. Only the fluorescent label signal (bright spot) can be extracted.
- the immunostained image of the reference biological material may be used only for obtaining the total luminance for correcting the fluorescent label signal (bright spot) of the target biological material.
- the measurement value of the fluorescent label signal corresponding to the target biological material in the cell membrane region is used for the entire measurement target region or for each cell, and the measurement value of the fluorescent label signal corresponding to the reference biological material is used. It is corrected and used as an index for quantifying the expression level.
- the way of correction is not particularly limited.
- the measurement value of each signal can be converted, converted, or compared by any method. Specifically, the number of bright spots of the fluorescent dye-encapsulated nanoparticles is used as the fluorescent labeling signal corresponding to the target biological substance, the total luminance of the fluorescent dye is used as the fluorescent labeling signal corresponding to the reference biological substance, and the former is divided by the latter. A method of correcting by dividing (dividing) is preferable.
- Such correction may be performed on the entire measurement target region of the first and second immunostained images (for example, the entire visual field or any other region of interest to be measured), or for each cell included therein. You may go to
- the sample is determined by quantifying the target biological material in the cell membrane region based on the index obtained in the correction step, that is, the correction value of the measured value of the fluorescent label signal corresponding to the target biological material in the cell membrane region. To obtain useful information for pathological diagnosis.
- the specimen evaluation method can be based on a conventional pathological diagnosis based on immunohistochemistry (IHC) staining.
- IHC immunohistochemistry
- HER2 Examination Guide for Herceptin Appropriate Case Selection September 2009, created by Trastuzumab Pathology Committee, 3rd edition.
- the correction value relating to the quantification of the expression level of HER2 on the cell membrane obtained by the method of the present invention is statistically compared with the result of Herceptin's response rate, thereby obtaining the conventional pathology.
- a score and determination similar to the diagnosis can be set, and a pathological diagnosis having effectiveness can be performed.
- kits for carrying out the target biological substance quantification method according to the present invention includes at least an antibody and a phosphor for producing an immunostaining agent for the target biological material, and an antibody and a phosphor for producing an immunostaining agent for the reference biological material.
- an immunostaining agent for a target biological material [primary antibody (probe)] ... [secondary antibody]-[biotin] / [avidin]-[fluorescent dye-containing nanoparticles] (Fluorescent substance)] so that a complex forming a complex can be prepared; primary antibody; secondary antibody-biotin conjugate, or secondary antibody, biotin and reaction reagent for preparing it; avidin-fluorescent dye inclusion Nanoparticle conjugates or those containing avidin, fluorescent dye-encapsulated nanoparticles and reaction reagents for preparing them are preferred.
- an immunostaining agent for a reference biological material a material that forms a complex of [primary antibody (probe)]...
- [Secondary antibody]-[fluorescent dye (fluorescent substance)] as described above can be prepared.
- Primary antibody Antibodies corresponding to each of two or more reference biological substances; secondary antibody-fluorescent dye conjugate or one containing a secondary antibody, a fluorescent dye and a reaction reagent for preparing it Is preferred.
- This kit further includes other necessary reagents and members for immunostaining pathological specimens as needed, and instructions for carrying out the target biological substance quantification method according to the present invention. Also good.
- Reagent II Preparation of biotin-modified anti-rabbit IgG antibody
- a 50 mM Tris solution 50 ⁇ g of an anti-rabbit IgG antibody used as a secondary antibody was dissolved.
- a DTT (dithiothreitol) solution was added to a final concentration of 3 mM, mixed, and reacted at 37 ° C. for 30 minutes. Thereafter, the reaction solution was passed through a desalting column “Zeba Desalt Spin Columns” (Thermo Scientific, Cat. # 89882) to purify the secondary antibody reduced with DTT.
- the linker reagent “Maleimide-PEG 2 -Biotin” (Thermo Scientific, product number 21901) was adjusted to 0.4 mM using DMSO. 8.5 ⁇ L of this linker reagent solution was added to the antibody solution, mixed, and reacted at 37 ° C. for 30 minutes to bind biotin to the anti-rabbit IgG antibody via the PEG chain. The reaction solution was purified through a desalting column.
- the absorbance at a wavelength of 300 nm was measured using a spectrophotometer (Hitachi “F-7000”) to calculate the concentration of the protein (biotin-modified secondary antibody) in the reaction solution.
- a solution in which the concentration of the biotin-modified secondary antibody was adjusted to 250 ⁇ g / mL using a 50 mM Tris solution was used as a biotin-modified secondary antibody (reagent II) solution.
- Nanoparticles 0.1 mg of washed particles X are dispersed in 1.5 mL of ethanol and aminopropyltrimethoxysilane “LS-3150” (Shin-Etsu Chemical Co., Ltd.) 2 ⁇ L was added, and a surface amination treatment was performed by reacting at room temperature with stirring for 8 hours.
- LS-3150 aminopropyltrimethoxysilane
- the concentration of the particle X having an aminated surface was adjusted to 3 nM using PBS containing 2 mM of EDTA (ethylenediaminetetraacetic acid), and a linker reagent “SM (PEG) 12 ” (manufactured by Thermo Scientific) was added to this solution. , Cat.No. 22112) was added and mixed to a final concentration of 10 mM, and reacted at room temperature for 1 hour with stirring. The reaction solution was centrifuged at 10,000 G for 20 minutes, and the supernatant was removed. Then, PBS containing 2 mM of EDTA was added to disperse the precipitate, and the mixture was centrifuged again under the same conditions. Washing by the same procedure was performed three times to obtain particles X surface-modified with a PEG chain having a maleimide group at the terminal.
- thiol group-introduced streptavidin was prepared as follows. First, 40 ⁇ L of an aqueous solution of streptavidin (Wako Pure Chemical Industries, Ltd.) adjusted to 1 mg / mL was added to N-succinimidyl-S-acetylthioacetate (N-succinimidyl S-acetylthioacetate, SATA, Pirce). A thiol group protected against the amino group of streptavidin (—NH—CO—CH 2 —S—CO—CH 3 ) was introduced by adding 70 ⁇ L of an aqueous solution of .
- a free thiol group (—SH) was generated from the protected thiol group by hydroxylamine treatment, and the treatment for introducing the thiol group (—SH) into streptavidin was completed.
- This solution was desalted by passing through a gel filtration column (Zaba Spin Desaling Columns: Funakoshi) to obtain streptavidin into which a thiol group was introduced.
- Example 1 (E1) Specimen Preparation Step and Specimen Pretreatment Step After the cultured breast cancer cell line CRL1500 was fixed using 4% paraformaldehyde, it was dehydrated, embedded and sliced according to a conventional method to prepare a sample. Three samples were prepared for each of a treatment group with a fixed treatment time of 1 hour, a treatment group with 12 hours, and a treatment group with 96 hours.
- the prepared specimen was deparaffinized and washed with water.
- the washed tissue array slide was autoclaved at 121 ° C. for 15 minutes in 10 mM citrate buffer (pH 6.0) to activate the antigen.
- the tissue array slide after the activation treatment was washed with PBS, and the washed tissue array slide was subjected to blocking treatment with PBS containing 1% BSA for 1 hour.
- Fluorescence labeling treatment for first immunostaining Reagent III streptavidin-modified Texas red dye-encapsulated melamine resin particles prepared in [Preparation Example] is 0.02 nM using PBS containing 1% of BSA. A fluorescent labeling reaction solution diluted to 1 was prepared. The specimen after the secondary reaction treatment was immersed in this fluorescent labeling solution and reacted at room temperature for 3 hours in a neutral pH environment (pH 6.9 to 7.4).
- E3 Evaluation step (E3-1) Observation / imaging step
- the fluorescence microscope “BX-53” (Olympus Co., Ltd.) was used for the excitation light irradiation and the fluorescence emission observation.
- the digital camera “DP73” (Olympus Corporation) attached to the fluorescent microscope was used for photographing.
- the specimen was irradiated with excitation light corresponding to the Texas Red dye used for fluorescent labeling of the target biological substance (HER2) to emit fluorescence, and an immunostained image in that state was photographed (first immunostained image).
- the wavelength of the excitation light was set to 575 to 600 nm using the excitation light optical filter provided in the fluorescence microscope, and the wavelength of the fluorescence to be observed was set to 612 to 692 nm using the fluorescence optical filter.
- the intensity of the excitation light at the time of observation and image photographing with a fluorescence microscope was such that the irradiation energy near the center of the visual field was 900 W / cm 2 .
- the exposure time at the time of image shooting was adjusted within a range in which the luminance of the image was not saturated, and was set to, for example, 4000 ⁇ sec.
- the optical filter for excitation light and the optical filter for fluorescence are switched, the sample is irradiated with excitation light corresponding to Alexa Fluor 647 used for the fluorescent labeling of the reference biological substance (cadherin), and the fluorescence is emitted.
- An immunostained image was taken (second immunostained image).
- the wavelength of the excitation light was set to 620 to 650 nm using the excitation light optical filter provided in the fluorescence microscope, and the wavelength of the fluorescence to be observed was set to 660 to 700 nm using the fluorescence optical filter.
- the intensity of the excitation light at the time of observation and image photographing with a fluorescence microscope was such that the irradiation energy near the center of the visual field was 400 W / cm 2 .
- the exposure time at the time of image shooting was adjusted within a range in which the luminance of the image was not saturated, and was set to 800 ms, for example.
- Such first and second immunostained images were taken in the same visual field, and then the same operation was repeated while changing the visual field, for a total of 5 visual fields per specimen (first to fifth visual fields).
- a region where the luminance of the fluorescence emitted by the phosphor is not less than a predetermined value corresponds to the “bright spot” corresponding to the cell membrane expressing the target biological material. Extracted as "measurement area”. In addition, the total (Y) intensity of fluorescence constituting the bright spot measurement region was obtained.
- the first immunostained image related to the target biological material HER2 is superimposed on the second immunostained image from which the bright spot measurement region is extracted, and the HER2 fluorescently labeled HER2 encapsulated in the region Among the bright spots representing melamine resin particles, the number (X) of the brightness having a predetermined value or more was measured.
- (E3-3) Correction Step For correction, a value obtained by dividing the X value by the Y value was calculated. After calculating such values for each of the first to fifth visual fields, an average value thereof was obtained and used as a “corrected HER2 quantitative value” used for evaluating the expression level of HER2.
- Example 2 Except that the breast cancer cell line used in the specimen preparation process was changed from CRL1500 to SK-BR3, the specimen preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 3 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to NDA-MB453, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 4 Except that the breast cancer cell line used in the specimen preparation process was changed from CRL1500 to NDA-MB175, the specimen preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 5 Except for changing the breast cancer cell line used in the specimen preparation process from CRL1500 to COLO201, the specimen preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. .
- Example 6 Except that the breast cancer cell line used in the specimen preparation process was changed from CRL1500 to Hela, the specimen preparation process, immunostaining process and evaluation process were performed in the same procedure as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. .
- Example 7 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to MCF-7, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 8 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to NDA-MB231, the sample preparation process, immunostaining process and evaluation process were performed in the same procedure as in Example 1, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 9 The reference biological material was changed from one type of cadherin to four types of ATPase, cadherin, cytokeratin, and EpCAM. That is, anti-HER2 rabbit monoclonal antibody “4B5” (Ventana) (reagent I) is contained at a concentration of 0.05 nM as the primary reaction treatment solution for the first and second immunostaining used in the immunostaining step.
- Example 10 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to SK-BR3, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 11 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to NDA-MB453, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 12 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to NDA-MB175, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 13 Except for changing the breast cancer cell line used in the specimen preparation process from CRL1500 to COLO201, the specimen preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. .
- Example 14 Except that the breast cancer cell line used in the specimen preparation process was changed from CRL1500 to Hela, the specimen preparation process, immunostaining process and evaluation process were performed in the same procedure as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. .
- Example 15 Except that the breast cancer cell line used in the sample preparation process was changed from CRL1500 to MCF-7, the sample preparation process, immunostaining process and evaluation process were performed in the same manner as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 16 Except that the breast cancer cell line used in the specimen preparation process was changed from CRL1500 to NDA-MB231, the specimen preparation process, immunostaining process and evaluation process were performed in the same procedure as in Example 9, and the coefficient of variation of the corrected HER2 quantitative value was calculated. Calculated.
- Example 17 A sample preparation step and an immunostaining step were performed in the same procedure as in Example 1 except that further HE staining was performed after the immunostaining step, and a coefficient of variation of the corrected HER2 quantitative value was calculated.
- the evaluation step in addition to the step of irradiating the sample with excitation light corresponding to the dye used for the fluorescent labeling of the target biological material and the reference biological material to emit fluorescence and photographing the immunostained image, the HE staining The process of taking a dyed image in a bright field was performed.
- Table 1 shows the coefficient of variation CV (%) of Reference Examples 1 to 8, Examples 1 to 8, and Examples 9 to 16.
- the CVs of Examples 1 to 8 are all 15% or less, and the numerical values are lower than the CVs of Reference Examples 1 to 8, that is, the variation is small.
- the target biological material can be used even when the specimen is a group including samples with various fixed conditions. It can be seen that a stable evaluation can be performed on the expression level of.
- the CVs of Examples 9 to 16 are all 10% or less, and the numerical values are lower than the CVs of Examples 1 to 8, that is, the variation is small. It can be seen that by making the reference biological material a mixture (cocktail) of a plurality of types, the expression level of the target biological material can be further stably evaluated.
- C2-1 First immunostaining step (immunostaining of target biological substance HER2)
- C2-1-1) Primary Reaction Treatment
- Anti-HER2 rabbit monoclonal antibody “4B5” Ventana
- Reagent I was adjusted to 0.05 nM using PBS containing 1% BSA.
- the specimen prepared in step (1) was immersed in this reagent I solution and reacted at 4 ° C. overnight.
- C2-1-2 Secondary reaction / fluorescence labeling treatment Secondary reaction in which Alexa Fluor 488 labeled anti-rabbit IgG antibody (Life Technologies, A11008) was diluted 1: 200 using PBS containing 1% BSA. A treatment solution was prepared. The specimen after the primary reaction treatment was washed with PBS, then immersed in this secondary reaction treatment solution, and reacted at room temperature for 30 minutes.
- C2-2 Second immunostaining step (immunostaining of reference biological substance ⁇ -actin) (C2-2-1) Primary reaction treatment A primary reaction treatment solution was prepared by diluting anti- ⁇ -actin antibody (Abcam, ab8229) 1: 200 using PBS containing 1% BSA. The specimen after the first immunostaining step was washed with PBS, then immersed in the primary reaction treatment solution and reacted at 4 ° C. overnight.
- C2-2-2 Secondary reaction / fluorescence labeling treatment Secondary reaction in which Alexa Fluor 647-labeled anti-mouse IgG antibody (Life Technology, A21236) was diluted 1: 200 using PBS containing 1% BSA. A treatment solution was prepared. The specimen after the primary reaction treatment was washed with PBS, then immersed in this secondary reaction treatment solution, and reacted at room temperature for 30 minutes.
- the sample was irradiated with excitation light corresponding to Alexa Fluor 488 used for fluorescent labeling of the target biological substance (HER2) to emit fluorescence, and an immunostained image in that state was photographed (first immunostained image).
- the wavelength of the excitation light was set to 460 to 490 nm using the excitation light optical filter provided in the fluorescence microscope, and the wavelength of the fluorescence to be observed was set to 500 to 540 nm using the fluorescence optical filter.
- the intensity of the excitation light at the time of observation with a fluorescence microscope and image capturing was such that the irradiation energy near the center of the visual field was 600 W / cm 2 .
- the exposure time at the time of image shooting was adjusted within a range in which the luminance of the image was not saturated, and was set to 800 ms, for example.
- the optical filter for excitation light and the optical filter for fluorescence are switched, and the sample is irradiated with excitation light corresponding to Alexa Fluor 647 used for fluorescent labeling of the reference biological substance ( ⁇ -actin) to emit fluorescence.
- An immunostained image of the state was taken (second immunostained image).
- the wavelength of the excitation light was set to 620 to 650 nm using the excitation light optical filter provided in the fluorescence microscope, and the wavelength of the fluorescence to be observed was set to 660 to 700 nm using the fluorescence optical filter.
- the intensity of the excitation light at the time of observation and image photographing with a fluorescence microscope was such that the irradiation energy near the center of the visual field was 400 W / cm 2 .
- the exposure time at the time of image shooting was adjusted within a range in which the luminance of the image was not saturated, and was set to 800 ms, for example.
- Such first and second immunostained images were taken in the same visual field, and then the same operation was repeated while changing the visual field, and a total of 3 visual fields were performed per specimen (first to third visual fields).
- the total intensity (X ′) of the fluorescence intensity emitted from the phosphor was determined.
- the second immunostained image related to ⁇ -actin which is a reference biological material, the total luminance (Y ′) of the fluorescence emitted by the phosphor was determined.
- (C3-3) Standardization step Standardization was performed by dividing the value of X ′ by the value of Y ′. After calculating such values for each of the first to third visual fields, the average value was obtained and used as the “HER2 quantitative value” used for evaluating the expression level of HER2.
- the CV was 22%, which was larger than the CV of the above-described example, that is, the variation was large.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Signal Processing (AREA)
- Dispersion Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
病理標本中の細胞膜に発現している生体物質(目的生体物質)の定量方法であって、
(1a)前記目的生体物質を、蛍光体を用いて免疫染色する工程、
(1b)前記細胞膜に恒常的に発現している前記目的生体物質とは異なる生体物質(参照生体物質)を、前記目的生体物質用の蛍光体とは異なる蛍光体を用いて免疫染色する工程、
(2)前記目的生体物質の免疫染色像および前記参照生体物質の免疫染色像を用いて、細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの位置を特定するとともに、前記細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルおよび前記参照生体物質に対応する蛍光標識シグナルを計測する工程、および
(3)測定対象領域全体について、または各細胞について、前記細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの計測値を、前記参照生体物質に対応する蛍光標識シグナルの計測値を用いて補正し、発現量を定量するための指標とする工程
を含む定量方法。
前記工程(3)として、細胞膜の領域内にある目的生体物質に対応する蛍光標識シグナルの計測値を、参照生体物質に対応する蛍光標識シグナルの計測値で除することで、シグナルの計測値を用いて補正し、発現量を定量するための指標とする工程を含む項1に記載の定量方法。
前記工程(1a)および(1b)の前後いずれかの工程で、明視野において形態の観察を行うための形態観察染色工程を含む項1または2に記載の定量方法。
前記形態観察染色工程がヘマトキシリン・エオジン染色である、請求項3に記載の定量方法。
前記工程(3)において、前記目的生体物質および前記目的生体物質に対応する蛍光標識シグナルの計測を550nm以上630nm以下の波長で行う、項3または4に記載の定量方法。
前記目的生体物質用の蛍光体が蛍光色素内包ナノ粒子であり、前記参照生体物質用の蛍光体が蛍光色素である、項1~5のいずれか一項に記載の定量方法。
前記蛍光色素内包ナノ粒子の平均粒径が50~200nmである、項6に記載の定量方法。
前記参照生体物質が2種類以上である、項1~7のいずれか一項に記載の定量方法。
前記参照生体物質が、ATPase、カドヘリン、サイトケラチンおよびEpCAMからなる群より選択される1種類または2種類以上である、項1~8のいずれか一項に記載の定量方法。
項1~9のいずれか一項に記載の目的生体物質の定量方法を実施するためのキットであって、
前記目的生体物質用の免疫染色剤を作製するための抗体および蛍光体、ならびに前記参照生体物質用の免疫染色剤を作製するための抗体および蛍光体を含むことを特徴とするキット。
本発明における第1の生体物質である目的生体物質は、組織切片の細胞膜に発現している生体物質、特にタンパク質(抗原)であって、主に病理診断の観点からの定量ないし検出のために、蛍光標識体を用いた免疫染色の対象とするものを指す。
本発明における第1の免疫染色剤は、目的生体物質を免疫染色によって蛍光標識化するための物質であって、少なくとも、目的生体物質に特異的に結合するプローブと、蛍光体とを含む。
第1免疫染色剤用のプローブ(第1プローブ)には、前述したような目的生体物質としてのタンパク質を抗原として特異的に認識して結合する抗体(IgG)を用いることができる。たとえば、EGFRを目的生体物質とする場合は抗EGFR抗体を、HER2を目的生体物質とする場合は抗HER2抗体を第1プローブとして用いることができる。
第1免疫染色剤用の蛍光体(第1蛍光体)および第2免疫染色剤用の蛍光体(第2蛍光体)は、当該技術分野において用いられている公知の各種の蛍光体の中から選択することができ、特に限定されるものではない。代表的な蛍光体としては、無機半導体ナノ粒子(「量子ドット」とも呼ばれる)、有機蛍光色素、およびこれらの集積体が挙げられる。
無機半導体ナノ粒子としては、II-VI族化合物、III-V族化合物、またはIV族元素を含有するもの、たとえば、CdSe、CdS、CdTe、ZnSe、ZnS、ZnTe、InP、InN、InAs、InGaP、GaP、GaAs、Si、Geなどが挙げられる。また、これらの無機半導体ナノ粒子をコアとし、その外側にシェルが形成されたもの、たとえば、CdSe/ZnS、CdS/ZnS、InP/ZnS、InGaP/ZnS、Si/SiO2、Si/ZnS、Ge/GeO2、Ge/ZnSなどのコア/シェル型無機半導体ナノ粒子を用いることもできる。
有機蛍光色素としては、ローダミン系色素分子、スクアリリウム系色素分子、シアニン系色素分子、芳香環系色素分子、オキサジン系色素分子、カルボピロニン系色素分子、ピロメセン系色素分子などを例示することができる。あるいは、Alexa Fluor(登録商標、インビトロジェン社製)系色素分子、BODIPY(登録商標、インビトロジェン社製)系色素分子、Cy(登録商標、GEヘルスケア社製)系色素分子、DY系色素分子(登録商標、DYOMICS社製)、HiLyte(登録商標、アナスペック社製)系色素分子、DyLight(登録商標、サーモサイエンティフィック社製)系色素分子、ATTO(登録商標、ATTO-TEC社製)系色素分子、MFP(登録商標、Mobitec社製)系色素分子などを用いることができる。なお、このような色素分子の総称は、化合物中の主要な構造(骨格)または登録商標に基づき命名されており、それぞれに属する蛍光色素の範囲は当業者であれば過度の試行錯誤を要することなく適切に把握できるものである。
蛍光物質の集積体として、有機物または無機物でできた粒子を母体とし、複数の蛍光物質がその中に内包されているおよび/またはその表面に吸着している構造を有する、ナノサイズの粒子である「蛍光物質集積ナノ粒子」が挙げられる。この場合、母体(たとえば樹脂)と蛍光物質(たとえば有機蛍光色素)は、互いに反対の電荷を有する置換基ないし部位を有しており、静電的相互作用が働くものであることが好適である。
第1蛍光体としては「蛍光色素内包ナノ粒子」が好ましく、第2蛍光体としては「蛍光色素」が好ましい。目的生体物質を蛍光標識する蛍光色素内包ナノ粒子は、目的生体物質を1分子ずつ輝点として表すのに十分な強度の蛍光を発することができ、また、参照生体物質を蛍光標識する蛍光色素は、目的生体物質のシグナル(前記輝点)を適切に補正することができる、標本作製時の劣化状態を反映した強度の蛍光を発することができるためである。
第1および第2免疫染色剤は、それぞれ目的生体物質および参照生体物質を蛍光標識し、病理診断のために有用なデータを得ることができるシグナルを発することができる限り、特に限定されるものではなく、公知の様々な免疫染色剤を用いることができる。そのような免疫染色剤としては、プローブおよび蛍光体が直接的に、つまり必要に応じてリンカー分子を介していてもよい、共有結合によって連結されているものを用いることもできるが、蛍光標識の効率を向上させて蛍光の劣化につながる時間経過をなるべく抑えるために、プローブおよび蛍光体が間接的に、つまり抗原抗体反応やアビジン・ビオチン反応などを利用した、共有結合以外の結合によって連結される複合体を用いることが好ましい。
本発明に係る目的生体物質の定量方法は、少なくとも下記の工程を含む:
(1a)目的生体物質を蛍光体を用いて免疫染色する工程(第1免疫染色工程);
(1b)参照生体物質を目的生体物質用の蛍光体とは異なる蛍光体を用いて免疫染色する工程(第2免疫染色工程);
(2)前記目的生体物質の免疫染色像および前記参照生体物質の免疫染色像について、前記目的生体物質に対応する蛍光標識シグナルおよび前記参照生体物質に対応する蛍光標識シグナルを計測し、細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルを抽出する工程(画像処理・計測工程):および
(3)測定対象領域全体について、または各細胞について、前記細胞膜の領域内にある目的生体物質に対応する蛍光標識シグナルの計測値を、参照生体物質に対応する蛍光標識シグナルの計測値を用いて補正し、発現量を定量するための指標とする工程(補正工程)。
病理標本は、細胞、組織、臓器などの切片がパラフィンに包埋された状態で保存されていることが多い。このような切片を免疫染色するためには、通常、免疫染色に先立って、切片の脱パラフィン処理、および抗原の賦活化処理が行われる。
(1a)第1免疫染色工程:目的生体物質の免疫染色
目的生体物質を免疫染色するための第1免疫染色工程は、前述したような第1免疫染色剤を用いて病理標本を免疫染色する工程である。第1免疫染色剤が、プローブと蛍光体とが直接的に連結しているものである場合は、その第1免疫染色剤を含む溶剤に賦活化工程を終えた病理標本を浸漬すればよい。一方、第1免疫染色剤が、プローブと蛍光体とが間接的に連結に結合している複合体である場合は、それらの複合体を形成するための複数の試薬に、病理標本を順次浸漬すればよい。
参照生体物質を免疫染色するための第2免疫染色工程は、前述したような第2免疫染色剤を用いて病理標本を免疫染色する工程である。第2免疫染色剤が、プローブと蛍光体とが直接的に連結しているものである場合は、その第2免疫染色剤を含む溶剤に賦活化工程を終えた病理標本を浸漬すればよい。一方、第2免疫染色剤が、プローブと蛍光体とが間接的に連結に結合している複合体である場合は、それらの複合体を形成するための複数の試薬に、病理標本を順次浸漬すればよい。
本発明では、もしも必要であれば、明視野において細胞、組織、臓器等の形態を観察することができるようにするための、形態観察染色工程を含めることができる。形態観察染色工程は、常法に従って行うことができる。組織標本の形態観察に関しては、細胞質・間質・各種線維・赤血球・角化細胞が赤~濃赤色に染色される、エオジンを用いた染色が標準的に用いられている。また、細胞核・石灰部・軟骨組織・細菌・粘液が青藍色~淡青色に染色される、ヘマトキシリンを用いた染色も標準的に用いられている(これら2つの染色を同時に行う方法はヘマトキシリン・エオジン染色(HE染色)として知られている)。形態観察染色工程を含める場合は、免疫染色工程の後に行うようにしてもよいし、免疫染色工程の前に行うようにしてもよい。
第1および第2免疫染色を終えた病理標本は、観察に適したものとなるよう、固定化・脱水、透徹、封入などの処理を行うことが好ましい。
観察・撮影工程では、第1免疫染色工程により得られる染色像(第1免疫染色像)および第2免疫染色工程により得られる染色像(第2免疫染色像)を取得する。具体的には、所望の倍率における顕微鏡の同一視野において、第1免疫染色工程に用いられた目的生体物質を蛍光標識している第1蛍光体に対応した励起光、および第2免疫染色工程に用いられた参照生体物質を蛍光標識している第2蛍光体に対応した励起光それぞれを病理標本に照射し、それらの蛍光体から発せられた蛍光による免疫染色像それぞれを観察・撮影する。観察工程における励起光は、組織切片の自家蛍光との関係で免疫染色剤用の蛍光体が発する蛍光が識別可能である限り特に限定されないものの、組織切片からの自家蛍光が高くなりすぎない観点から、550~630nmの波長を有する励起光が好ましい。これらの励起光の照射は、たとえば、蛍光顕微鏡が備えるレーザー光源と、必要に応じて所定の波長を選択的に透過させる励起光用フィルターを用いることで照射することができる。第1蛍光体に対する励起光の波長と第2蛍光体に対する励起光の波長が異なる場合は、励起光用フィルターを切り替えることで、同一のレーザー光源から両方の波長の励起光を照射することができる。免疫染色像の撮影は、たとえば、蛍光顕微鏡が備えるデジタルカメラによって行うことができる。免疫染色像の撮影の際には、必要に応じて所定の波長を選択的に透過させる蛍光用フィルターを用いることで、目的とする蛍光のみを含み、目的としない蛍光やノイズとなる励起光およびその他の光を排除した免疫染色像を撮影することができる。第1蛍光体が発する蛍光の波長と第2蛍光体が発する蛍光の波長は、互いの蛍光を区別できるよう異なるものとする必要があるので、蛍光用フィルターを切り替えながら、それぞれの蛍光の免疫染色像を撮影すればよい。
画像処理・計測工程では、目的生体物質に関して撮影された第1免疫染色像、および参照生体物質に関して撮影された第2免疫染色像のそれぞれについて、画像処理に基づき、目的生体物質に対応する蛍光標識シグナルおよび参照生体物質に対応する蛍光標識シグナルを計測し、細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの位置を特定する。
第1実施形態は、次の工程(2a-1)、(2a-2)および(2a-3)を含む:
(2a-1)参照生体物質の免疫染色像(図3参照)から蛍光色素の輝点を抽出して細胞膜領域像を形成すると共に、その細胞膜領域内の輝点の輝度の総和を参照生体物質の蛍光標識シグナルとして計測する工程;
(2a-2)細胞膜領域像に目的生体物質の免疫染色像(図2参照)を重ねあわせ(図4参照)、細胞膜領域の内側にある蛍光色素内包ナノ粒子の輝点数を目的生体物質の蛍光標識シグナルとして計測する工程;
(2a-3)細胞膜領域内の輝点数を蛍光色素の輝度の総和で除することで補正された計測値をもって、目的生体物質の発現量を定量するための指標値とする工程。
第2実施形態は、次の工程(2b-1)、(2b-2)および(2b-3)を含む:
(2b-1)目的生体物質の免疫染色像(図2参照)から、輝点抽出プログラムに従って蛍光色素内包ナノ粒子の輝点を抽出して細胞膜領域像を形成すると共に、その細胞膜領域内の輝点数を前記目的生体物質の蛍光標識シグナルとして計測する工程;
(2b-2)参照生体物質の免疫染色像(図3参照)と細胞膜領域とを重ねあわせ、細胞膜領域の内側にある蛍光色素の輝度の総和を参照生体物質の蛍光標識シグナルとして計測する工程;
(2b-3)細胞膜領域内の輝点数を蛍光色素の輝度の総和で除することで補正された計測値をもって、目的生体物質の発現量を定量するための指標値とする工程。
補正工程では、測定対象領域全体について、または各細胞について、細胞膜の領域内にある目的生体物質に対応する蛍光標識シグナルの計測値を、参照生体物質に対応する蛍光標識シグナルの計測値を用いて補正し、発現量を定量するための指標とする。補正の仕方は特に限定されるものではないが、たとえば、それぞれのシグナルの計測値を、換算、変換、あるいは比較などを任意の方法で行うことができる。具体的には、目的生体物質に対応する蛍光標識シグナルとして蛍光色素内包ナノ粒子の輝点数を用い、参照生体物質に対応する蛍光標識シグナルとして蛍光色素の輝度の総和を用い、前者を後者で除する(割る)ことで補正する方法が好ましい。
評価工程では、補正工程で得られた指標、すなわち細胞膜の領域内にある目的生体物質に対応する蛍光標識シグナルの計測値の補正値に基づき、細胞膜領域内の目的生体物質を定量することで標本の評価を行い、病理診断のために有用な情報を取得する。
本発明の別の側面において、本発明に係る目的生体物質の定量方法を実施するためのキットが提供される。このキットは少なくとも、目的生体物質用の免疫染色剤を作製するための抗体および蛍光体、ならびに参照生体物質用の免疫染色剤を作製するための抗体および蛍光体を含む。
50mMTris溶液に、2次抗体として用いる抗ウサギIgG抗体50μgを溶解した。この溶液に、最終濃度3mMとなるようにDTT(ジチオトレイトール)溶液を添加、混合し、37℃で30分間反応させた。その後、反応溶液を脱塩カラム「Zeba Desalt Spin Columns」(サーモサイエンティフィック社、Cat.#89882)に通して、DTTで還元化した2次抗体を精製した。精製した抗体全量のうち200μLを50mMTris溶液に溶解して抗体溶液を調製した。その一方で、リンカー試薬「Maleimide-PEG2-Biotin」(サーモサイエンティフィック社、製品番号21901)を、DMSOを用いて0.4mMとなるように調整した。このリンカー試薬溶液8.5μLを前記抗体溶液に添加、混合し、37℃で30分間反応させることにより、抗ウサギIgG抗体にPEG鎖を介してビオチンを結合させた。この反応溶液を脱塩カラムに通して精製した。脱塩した反応溶液について、波長300nmにおける吸光度を分光高度計(日立製「F-7000」)を用いて測定することにより、反応溶液中のタンパク質(ビオチン修飾2次抗体)の濃度を算出した。50mMTris溶液を用いて、ビオチン修飾2次抗体の濃度を250μg/mLに調整した溶液を、ビオチン修飾2次抗体(試薬II)の溶液とした。
(1)テキサスレッド色素内包メラミン樹脂ナノ粒子の調製
テキサスレッド色素分子「Sulforhodamine 101」(シグマアルドリッチ社)2.5mgを純水22.5mLに溶解した後、ホットスターラーにより溶液の温度を70℃に維持ながら20分間撹拌した。撹拌後の溶液に、メラミン樹脂「ニカラックMX-035」(日本カーバイド工業株式会社)1.5gを加え、さらに同一条件で5分間加熱撹拌した。撹拌後の溶液にギ酸100μLを加え、溶液の温度を60℃に維持しながら20分間攪拌した後、その溶液を放置して室温まで冷却した。冷却した後の溶液を複数の遠心用チューブに分注して、12,000rpmで20分間遠心分離して、溶液に混合物として含まれるテキサスレッド色素内包メラミン樹脂ナノ粒子(以下、粒子Xと略称する。)を沈殿させた。上澄みを除去し、沈殿した粒子Xをエタノールおよび水で洗浄した。
洗浄後の粒子X0.1mgをエタノール1.5mL中に分散し、アミノプロピルトリメトキシシラン「LS-3150」(信越化学工業株式会社)2μLを加えて8時間、撹拌しながら室温で反応させて表面アミノ化処理を行った。表面がアミノ化された粒子Xの濃度を、EDTA(エチレンジアミン四酢酸)を2mM含有したPBSを用いて3nMに調整し、この溶液にリンカー試薬「SM(PEG)12」(サーモサイエンティフィック社製、cat.No. 22112)を最終濃度10mMとなるよう添加、混合して、撹拌しながら室温で1時間反応させた。反応液を10,000Gで20分間の遠心分離にかけ、上澄みを除去した後、EDTAを2mM含有したPBSを加えて沈降物を分散させ、同一条件で再度遠心分離を行った。同様の手順による洗浄を3回行うことで、末端にマレイミド基を有するPEG鎖で表面修飾された粒子Xを得た。
一方、チオール基を導入したストレプトアビジンは以下のようにして作製した。まず、1mg/mLに調整したストレプトアビジン(和光純薬工業株式会社)の水溶液40μLに、64mg/mLに調整したN-スクシンイミジル-S-アセチルチオアセテート(N-succinimidyl S-acetylthioacetate,SATA、pirce社製)の水溶液70μLを加え、室温で1時間より反応させることにより、ストレプトアビジンのアミノ基に対して保護されたチオール基(-NH-CO-CH2-S-CO-CH3)を導入した。続いて、ヒドロキシルアミン処理により、保護されたチオール基から遊離のチオール基(-SH)を生成させて、ストレプトアビジンにチオール基(-SH)を導入する処理を完了させた。この溶液をゲルろ過カラム(Zaba Spin Desalting Columns:フナコシ)に通して脱塩し、チオール基を導入したストレプトアビジンを得た。
(2)で調製した末端にマレイミド基を有するPEG鎖で表面修飾された粒子X(テキサスレッド色素内包メラミン樹脂ナノ粒子)と、(3)で調製したチオール基を導入したストレプトアビジンとを、EDTAを2mM含有するPBS中で混合し、1時間反応させることで、粒子XにPEG鎖を介してストレプトアビジンを結合させた。この反応液に10mMメルカプトエタノールを添加し、反応を停止させた。得られた溶液を遠心フィルターで濃縮後、精製用ゲルろ過カラムを用いて未反応物を除去し、ストレプアビジンで修飾された粒子X(試薬III)を得た。
(E1)標本作製工程および標本前処理工程
培養した乳癌細胞株CRL1500を、4%パラホルムアルデヒドを用いて固定処理した後、常法に従って脱水、包埋および薄切し、標本を作製した。この際の固定処理時間を1時間とした処理群、12時間とした処理群、96時間とした処理群、それぞれ3つずつ標本を作製した。
(E2-1)第1・第2免疫染色用共通の1次反応処理
目的生体物質HER2に係る第1免疫染色用の1次反応処理と、参照生体物質カドヘリンに係る第2免疫染色用の1次反応処理は、両方の1次反応処理用の抗体を溶解させた反応処理液を用いて一度に行った。すなわち、BSAを1%含有するPBSを用いて、抗HER2ウサギモノクローナル抗体「4B5」(ベンタナ社)(試薬I)を0.05nMの濃度で含有するとともに、抗パン(Anti-pan)カドヘリン抗体[CH-19](アブカム社、ab6528)を1:200に希釈した濃度で含有する1次反応処理液を調製した。この1次反応処理液に工程(1)で作製した標本を浸漬し、4℃で1晩反応させた。
[作製例]で作製した試薬II(ビオチン修飾抗ウサギIgG抗体)の溶液を、さらにBSAを1%含有するPBSを用いて6μg/mLに希釈した2次反応処理液を調製した。1次反応処理を終えた標本をPBSで洗浄した後、この2次反応処理液に浸漬し、室温で30分間反応させた。
[作製例]で作製した試薬III(ストレプトアビジン修飾テキサスレッド色素内包メラミン樹脂粒子)を、BSAを1%含有するPBSを用いて0.02nMに希釈した蛍光標識反応処理液を調製した。2次反応処理を終えた標本をこの蛍光標識処理液に浸漬し、中性のpH環境下(pH6.9~7.4)、室温で3時間反応させた。
BSAを1%含有するPBSを用いてAlexa Fluor 647標識化抗マウスIgG抗体(ライフテクノロジー社、A21236)を1:200に希釈した2次反応処理液を調製した。1次反応処理を終えた標本をPBSで洗浄した後、この2次反応処理液に浸漬し、室温で30分間反応させた。
第1および第2免疫染色を終えた標本に対して、純エタノールに5分間浸漬する操作を4回行う固定化・脱水処理を行った。続いて、キシレンに5分間浸漬する操作を4回行う透徹処理を行った。最後に、標本に封入剤「エンテランニュー」(メルク社)を載せて、カバーガラスを被せる封入処理を行い、観察に用いる標本とした。
(E3-1)観察・撮影工程
この工程における励起光の照射および蛍光の発光の観察には蛍光顕微鏡「BX-53」(オリンパス株式会社)を用い、免疫染色像(400倍)の撮影には、当該蛍光顕微鏡に取り付けた顕微鏡用デジタルカメラ「DP73」(オリンパス株式会社)を用いた。
この工程における画像処理には、画像処理ソフトウェア「ImageJ」(オープンソース)を用いた。
補正のために、前記Xの値を前記Yの値で割った値を算出した。このような値を第1~第5視野のそれぞれについて算出した後、それらの平均値を求め、HER2の発現量を評価するために用いる"補正HER2定量値"とした。
標本作製工程で用いた乳癌細胞株をCRL1500からSK-BR3に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB453に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB175に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からCOLO201に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からHelaに変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からMCF-7に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB231に変更した以外は、実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
参照生体物質を、カドヘリン1種類から、ATPase、カドヘリン、サイトケラチンおよびEpCAMの4種類に変更した。すなわち、免疫染色工程に用いた、第1・第2免疫染色用の1次反応処理液として、抗HER2ウサギモノクローナル抗体「4B5」(ベンタナ社)(試薬I)を0.05nMの濃度で含有するとともに、抗パンカドヘリン抗体(Anti-pan Cadherin antibody)[CH-19](アブカム社、ab6528)、抗α1 Na+/K+ ATPase抗体(Anti-alpha 1 Sodium Potassium ATPase antibody)[464.6]-原形質膜マーカー(Plasma Membrane Marker)(アブカム社、ab7671)、抗パンサイトケラチン抗体(Anti-pan Cytokeratin antibody)[PCK-26](アブカム社、ab6401)および抗EpCAM抗体「VU1D9」(アブカム社)それぞれを1:200に希釈した濃度で含有するものを用いた。それ以外は実施例1と同様の手順で標本作製工程、免疫染色工程および評価工程を行った。
標本作製工程で用いた乳癌細胞株をCRL1500からSK-BR3に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB453に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB175に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からCOLO201に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からHelaに変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からMCF-7に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
標本作製工程で用いた乳癌細胞株をCRL1500からNDA-MB231に変更した以外は、実施例9と同様の手順で標本作製工程、免疫染色工程および評価工程を行い、補正HER2定量値の変動係数を算出した。
免疫染色工程の後に、さらにHE染色を行なった以外は、実施例1と同様の手順で標本作製工程および免疫染色工程を行い、補正HER2定量値の変動係数を算出した。ここで評価工程においては、目的生体物質および参照生体物質の蛍光標識に用いた色素に対応する励起光を標本に照射して蛍光を発光させて免疫染色像を撮影する工程に加えて、HE染色による染色像を明視野にて撮影する工程を行った。
実施例1の評価工程中の画像処理・計測工程において、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、HER2の発現量を評価するために用いる"非補正HER2定量値"とし、その変動係数CVを算出した。
実施例2の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例3の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例4の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例5の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例6の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例7の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
実施例8の評価工程中の画像処理・計測工程において、参考例1と同様、前記Xの値を前記Yの値で割る補正を行わず、前記Yの値自体について第1~第5視野の平均値を求め、非補正HER2定量値の変動係数を算出した。
参考例1~8、実施例1~8および実施例9~16の変動係数CV(%)を表1に示す。実施例1~8のCVはいずれも15%以下であり、それぞれ参考例1~8のCVよりも数値が低い、つまりばらつきが小さい。参照生体物質の蛍光標識シグナル(輝度)を用いて目的生体物質の蛍光標識シグナル(輝点数)を補正することにより、標本が様々な固定条件のものを含む集団である場合にも、目的生体物質の発現量について安定した評価を行えることが分かる。また、実施例9~16のCVはいずれも10%以下であり、それぞれ実施例1~8のCVよりもさらに数値が低い、つまりばらつきが小さい。参照生体物質を複数の種類の混合物(カクテル)とすることにより、さらに目的生体物質の発現量について安定した評価を行えることが分かる。
特許文献2(特開2008-286167号公報)の実施例に記載された方法に準じて、細胞質内で発現するβ-アクチンを参照生体物質とし、また目的生体物質のHER2を蛍光色素内包樹脂ナノ粒子ではなく蛍光色素自体で蛍光標識する免疫染色工程を行った。
具体的には次の通りである。
(C2-1-1)1次反応処理
BSAを1%含有するPBSを用いて、抗HER2ウサギモノクローナル抗体「4B5」(ベンタナ社)(試薬I)を0.05nMに調整した。この試薬Iの溶液に工程(1)で作製した標本を浸漬し、4℃で1晩反応させた。
BSAを1%含有するPBSを用いてAlexa Fluor 488標識化抗ウサギIgG抗体(ライフテクノロジー社、A11008)を1:200に希釈した2次反応処理液を調製した。1次反応処理を終えた標本をPBSで洗浄した後、この2次反応処理液に浸漬し、室温で30分間反応させた。
(C2-2-1)1次反応処理
BSAを1%含有するPBSを用いて、抗β-アクチン抗体(アブカム社、ab8229)を1:200に希釈した1次反応処理液を調製した。第1免疫染色工程を終えた標本をPBSで洗浄した後、この1次反応処理液に浸漬し、4℃で1晩反応させた。
BSAを1%含有するPBSを用いてAlexa Fluor 647標識化抗マウスIgG抗体(ライフテクノロジー社、A21236)を1:200に希釈した2次反応処理液を調製した。1次反応処理を終えた標本をPBSで洗浄した後、この2次反応処理液に浸漬し、室温で30分間反応させた。
第1および第2免疫染色工程を終えた標本に対して、純エタノールに5分間浸漬する操作を4回行う固定化・脱水処理を行った。続いて、キシレンに5分間浸漬する操作を4回行う透徹処理を行った。最後に、標本に封入剤「エンテランニュー」(メルク社)を載せて、カバーガラスを被せる封入処理を行い、観察に用いる標本とした。
特許文献2(特開2008-286167号公報)の実施例に記載された方法に準じて、目的生体物質HER2を標識する蛍光の総和を、参照生体物質β-アクチンを標識する蛍光の総和で割った値をHER2定量値として参照する評価工程を行った。具体的には次の通りである。
この工程における励起光の照射および蛍光の発光の観察には蛍光顕微鏡「BX-53」(オリンパス株式会社)を用い、免疫染色像(400倍)の撮影には、当該蛍光顕微鏡に取り付けた顕微鏡用デジタルカメラ「DP73」(オリンパス株式会社)を用いた。
この工程における画像処理には、画像処理ソフトウェア「ImageJ」(オープンソース)を用いた。
X'の値をY'の値で割って標準化した。このような値を第1~第3視野のそれぞれについて算出した後、それらの平均値を求め、HER2の発現量を評価するために用いる"HER2定量値"とした。
Claims (10)
- 病理標本中の細胞膜に発現している生体物質(目的生体物質)の定量方法であって、
(1a)前記目的生体物質を、蛍光体を用いて免疫染色する工程、
(1b)前記細胞膜に恒常的に発現している前記目的生体物質とは異なる生体物質(参照生体物質)を、前記目的生体物質用の蛍光体とは異なる蛍光体を用いて免疫染色する工程、
(2)前記目的生体物質の免疫染色像および前記参照生体物質の免疫染色像を用いて、細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの位置を特定するとともに、前記細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの位置および前記参照生体物質に対応する蛍光標識シグナルを計測する工程、および
(3)測定対象領域全体について、または各細胞について、前記細胞膜の領域内にある前記目的生体物質に対応する蛍光標識シグナルの計測値を、前記参照生体物質に対応する蛍光標識シグナルの計測値を用いて補正し、発現量を定量するための指標とする工程
を含む定量方法。 - 前記工程(3)として、細胞膜の領域内にある目的生体物質に対応する蛍光標識シグナルの計測値を、参照生体物質に対応する蛍光標識シグナルの計測値で除することで、シグナルの計測値を用いて補正し、発現量を定量するための指標とする工程を含む請求項1に記載の定量方法。
- 前記工程(1a)および(1b)の前後いずれかの工程で、明視野において形態の観察を行うための形態観察染色工程を含む請求項1または2に記載の定量方法。
- 前記形態観察染色工程がヘマトキシリン・エオジン染色である、請求項3に記載の定量方法。
- 前記工程(3)において、前記目的生体物質および前記目的生体物質に対応する蛍光標識シグナルの計測を550nm以上630nm以下の波長で行う、請求項3または4に記載の定量方法。
- 前記目的生体物質用の蛍光体が蛍光色素内包ナノ粒子であり、前記参照生体物質用の蛍光体が蛍光色素である、請求項1~5のいずれか一項に記載の定量方法。
- 前記蛍光色素内包ナノ粒子の平均粒径が50~200nmである、請求項6に記載の定量方法。
- 前記参照生体物質が2種類以上である、請求項1~7のいずれか一項に記載の定量方法。
- 前記参照生体物質が、ATPase、カドヘリン、サイトケラチンおよびEpCAMからなる群より選択される1種類または2種類以上である、請求項1~8のいずれか一項に記載の定量方法。
- 請求項1~9のいずれか一項に記載の目的生体物質の定量方法を実施するためのキットであって、
前記目的生体物質用の免疫染色剤を作製するための抗体および蛍光体、ならびに前記参照生体物質用の免疫染色剤を作製するための抗体および蛍光体を含むことを特徴とするキット。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015531968A JP5843054B1 (ja) | 2014-03-24 | 2015-03-23 | 多重免疫染色法に基づく生体物質の定量方法 |
EP15770205.1A EP3124969B1 (en) | 2014-03-24 | 2015-03-23 | Biological-material quantitation method based on multiple-antigen immunostaining |
US15/124,557 US20170016911A1 (en) | 2014-03-24 | 2015-03-23 | Method for quantifying biological material based on multiple immunostaining |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-059883 | 2014-03-24 | ||
JP2014059883 | 2014-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015146896A1 true WO2015146896A1 (ja) | 2015-10-01 |
Family
ID=54195409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/058703 WO2015146896A1 (ja) | 2014-03-24 | 2015-03-23 | 多重免疫染色法に基づく生体物質の定量方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170016911A1 (ja) |
EP (1) | EP3124969B1 (ja) |
JP (1) | JP5843054B1 (ja) |
WO (1) | WO2015146896A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017104476A1 (ja) * | 2015-12-18 | 2017-06-22 | コニカミノルタ株式会社 | 蛍光物質集積ナノ粒子およびそれを用いた標識剤 |
EP3321682A1 (en) | 2016-11-11 | 2018-05-16 | Konica Minolta, Inc. | Test support method for supporting prediction of pathological complete response (pcr) using fluorescent nanoparticles |
WO2018185943A1 (ja) | 2017-04-07 | 2018-10-11 | コニカミノルタ株式会社 | 蛍光プレミックス粒子、それを含有する蛍光染色液、およびそれらを用いた蛍光染色法 |
EP3418745A4 (en) * | 2016-02-19 | 2018-12-26 | Konica Minolta, Inc. | Information acquisition method for diagnosis or treatment of cancer or immune system-related diseases |
EP3441761A4 (en) * | 2016-04-06 | 2019-04-10 | Konica Minolta, Inc. | FLUORESCENT IMMUNOCOLORATION METHOD |
JP2019100945A (ja) * | 2017-12-06 | 2019-06-24 | キヤノンメディカルシステムズ株式会社 | タンパク質をイメージングする方法 |
JPWO2018185942A1 (ja) * | 2017-04-07 | 2020-02-13 | コニカミノルタ株式会社 | タンパク質修飾蛍光体集積粒子の精製物を製造する方法、蛍光染色液の製造方法、タンパク質修飾蛍光体集積粒子の精製物、蛍光染色液およびタンパク質修飾蛍光体集積粒子精製用フィルター |
WO2020255906A1 (ja) * | 2019-06-20 | 2020-12-24 | コニカミノルタ株式会社 | 蛍光標識剤用連結体 |
WO2022264545A1 (ja) * | 2021-06-17 | 2022-12-22 | コニカミノルタ株式会社 | 定量方法および標識方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3779433A3 (en) | 2010-08-30 | 2021-05-19 | Konica Minolta, Inc. | Tissue staining method, tissue evaluation method and biosubstance detection method |
US20230288427A1 (en) * | 2020-05-29 | 2023-09-14 | Sony Group Corporation | Information processing apparatus, biological specimen analysis method, biological specimen detection apparatus, and biological specimen detection system |
CN112985952B (zh) * | 2021-02-20 | 2022-09-20 | 山东骏腾医疗科技有限公司 | 一种病理封片材料 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008268167A (ja) * | 2007-03-29 | 2008-11-06 | Saga Univ | 蛍光多重染色による蛋白定量法 |
JP2009536355A (ja) * | 2006-05-05 | 2009-10-08 | イェール ユニバーシティー | 診断指標または予測指標としての細胞内局在プロフィールの使用 |
WO2012029342A1 (ja) * | 2010-08-30 | 2012-03-08 | コニカミノルタエムジー株式会社 | 組織染色方法、組織評価方法および生体物質検出方法 |
WO2012029752A1 (ja) * | 2010-08-31 | 2012-03-08 | コニカミノルタエムジー株式会社 | 生体物質検出方法 |
JP5039264B2 (ja) * | 2000-01-24 | 2012-10-03 | ダコ・デンマーク・エー/エス | マーカー指数の内部の質的および量的な検証のためのシステム |
JP2013057631A (ja) * | 2011-09-09 | 2013-03-28 | Konica Minolta Medical & Graphic Inc | 生体物質発現レベル評価システム |
WO2015045962A1 (ja) * | 2013-09-26 | 2015-04-02 | コニカミノルタ株式会社 | 組織切片における生体物質の定量法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642062B2 (en) * | 1998-09-03 | 2003-11-04 | Trellis Bioinformatics, Inc. | Multihued labels |
US6682927B2 (en) * | 1998-10-05 | 2004-01-27 | Duke University | Methods and apparatus for the high through-put detection of binding interactions in vivo |
US7219016B2 (en) * | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
CA2450725A1 (en) * | 2001-06-28 | 2003-01-09 | Advanced Research And Technology Institute, Inc. | Methods of preparing multicolor quantum dot tagged beads and conjugates thereof |
US20060160168A1 (en) * | 2005-01-14 | 2006-07-20 | The General Hospital Corporation | Methods and products for identifying compounds that modulate cell plasma membrane repair |
JP2007271503A (ja) * | 2006-03-31 | 2007-10-18 | Nikon Corp | 細胞機能の評価方法、細胞機能の評価システム、蛍光顕微鏡システム、光治療方法、及び光治療システム |
US8131476B2 (en) * | 2006-08-07 | 2012-03-06 | General Electric Company | System and method for co-registering multi-channel images of a tissue micro array |
AU2010204741B2 (en) * | 2009-01-14 | 2016-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ratio based biomarkers and methods of use thereof |
WO2011042874A1 (en) * | 2009-10-06 | 2011-04-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Visualization of proprotein convertase activity in living cells and tissues |
US9483684B2 (en) * | 2012-03-30 | 2016-11-01 | Konica Minolta, Inc. | Medical image processor and storage medium |
WO2013151511A1 (en) * | 2012-04-05 | 2013-10-10 | Agency For Science, Technology And Research | Modified Dual-Colour Protein |
-
2015
- 2015-03-23 JP JP2015531968A patent/JP5843054B1/ja active Active
- 2015-03-23 EP EP15770205.1A patent/EP3124969B1/en active Active
- 2015-03-23 WO PCT/JP2015/058703 patent/WO2015146896A1/ja active Application Filing
- 2015-03-23 US US15/124,557 patent/US20170016911A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5039264B2 (ja) * | 2000-01-24 | 2012-10-03 | ダコ・デンマーク・エー/エス | マーカー指数の内部の質的および量的な検証のためのシステム |
JP2009536355A (ja) * | 2006-05-05 | 2009-10-08 | イェール ユニバーシティー | 診断指標または予測指標としての細胞内局在プロフィールの使用 |
JP2008268167A (ja) * | 2007-03-29 | 2008-11-06 | Saga Univ | 蛍光多重染色による蛋白定量法 |
WO2012029342A1 (ja) * | 2010-08-30 | 2012-03-08 | コニカミノルタエムジー株式会社 | 組織染色方法、組織評価方法および生体物質検出方法 |
WO2012029752A1 (ja) * | 2010-08-31 | 2012-03-08 | コニカミノルタエムジー株式会社 | 生体物質検出方法 |
JP2013057631A (ja) * | 2011-09-09 | 2013-03-28 | Konica Minolta Medical & Graphic Inc | 生体物質発現レベル評価システム |
WO2015045962A1 (ja) * | 2013-09-26 | 2015-04-02 | コニカミノルタ株式会社 | 組織切片における生体物質の定量法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3124969A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017104476A1 (ja) * | 2015-12-18 | 2017-06-22 | コニカミノルタ株式会社 | 蛍光物質集積ナノ粒子およびそれを用いた標識剤 |
JPWO2017104476A1 (ja) * | 2015-12-18 | 2018-10-04 | コニカミノルタ株式会社 | 蛍光物質集積ナノ粒子およびそれを用いた標識剤 |
EP3418745A4 (en) * | 2016-02-19 | 2018-12-26 | Konica Minolta, Inc. | Information acquisition method for diagnosis or treatment of cancer or immune system-related diseases |
EP3441761A4 (en) * | 2016-04-06 | 2019-04-10 | Konica Minolta, Inc. | FLUORESCENT IMMUNOCOLORATION METHOD |
EP3321682A1 (en) | 2016-11-11 | 2018-05-16 | Konica Minolta, Inc. | Test support method for supporting prediction of pathological complete response (pcr) using fluorescent nanoparticles |
WO2018185943A1 (ja) | 2017-04-07 | 2018-10-11 | コニカミノルタ株式会社 | 蛍光プレミックス粒子、それを含有する蛍光染色液、およびそれらを用いた蛍光染色法 |
JPWO2018185942A1 (ja) * | 2017-04-07 | 2020-02-13 | コニカミノルタ株式会社 | タンパク質修飾蛍光体集積粒子の精製物を製造する方法、蛍光染色液の製造方法、タンパク質修飾蛍光体集積粒子の精製物、蛍光染色液およびタンパク質修飾蛍光体集積粒子精製用フィルター |
JP2019100945A (ja) * | 2017-12-06 | 2019-06-24 | キヤノンメディカルシステムズ株式会社 | タンパク質をイメージングする方法 |
JP7262922B2 (ja) | 2017-12-06 | 2023-04-24 | キヤノンメディカルシステムズ株式会社 | タンパク質をイメージングする方法 |
WO2020255906A1 (ja) * | 2019-06-20 | 2020-12-24 | コニカミノルタ株式会社 | 蛍光標識剤用連結体 |
WO2022264545A1 (ja) * | 2021-06-17 | 2022-12-22 | コニカミノルタ株式会社 | 定量方法および標識方法 |
Also Published As
Publication number | Publication date |
---|---|
US20170016911A1 (en) | 2017-01-19 |
EP3124969A4 (en) | 2017-11-29 |
EP3124969B1 (en) | 2019-05-01 |
JP5843054B1 (ja) | 2016-01-13 |
EP3124969A1 (en) | 2017-02-01 |
JPWO2015146896A1 (ja) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5843054B1 (ja) | 多重免疫染色法に基づく生体物質の定量方法 | |
US11435348B2 (en) | Tissue staining method | |
US10509039B2 (en) | Integrated phosphor nanoparticle marking agent, and fluorescent immunostaining employing same | |
JP6687018B2 (ja) | 目的生体物質の検出方法および検出システム | |
US11662348B2 (en) | Method for detecting constituent component of antibody-drug conjugate | |
US11391728B2 (en) | Phosphor-integrated nanoparticles used in fluorescence observation | |
US20200363389A1 (en) | Method for Assessing Medicine | |
WO2017175523A1 (ja) | 蛍光免疫染色法 | |
JP6658330B2 (ja) | 組織切片から蛍光ナノ粒子の解離を防止する方法 | |
US20210011007A1 (en) | Fluorescent premix particles, fluorescent stain containing same, and fluorescent staining method in which these are used | |
JP6725045B2 (ja) | 蛍光ナノ粒子用希釈液、これを用いた蛍光免疫染色用キット、蛍光免疫染色用溶液、および蛍光免疫染色法、遺伝子染色法 | |
JP6583011B2 (ja) | 酸性水溶液を用いた免疫染色スライドの洗浄方法 | |
JPWO2012124763A1 (ja) | 組織評価方法 | |
JP6769360B2 (ja) | 蛍光体集積粒子複合体を用いた多段階蛍光染色方法および蛍光体集積粒子複合体 | |
WO2021039592A1 (ja) | 創薬支援方法、創薬支援装置及びプログラム | |
WO2019130503A1 (ja) | 情報取得方法 | |
JP6398419B2 (ja) | ソラフェニブを含有する標識剤 | |
WO2020050373A1 (ja) | 情報取得方法、情報取得装置及びプログラム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2015531968 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15770205 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015770205 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015770205 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15124557 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |